Abstract： Objective:To observe the clinical efficacy and safety of Conbercept Ophthalmic Injection in the treatment of wet age-related macular degeneration(wAMD), and to explore the relevant factors that affect its prognosis.Methods:The data of 61 patients(65 eyes)with wAMD were retrospectively collected, and they received the 3?+?PRN intravitreal treatments of Conbercept 0.5 mg/0.05ml. The best corrected visual acuity(BCVA)and OCT were performed at 1, 2, 3, 6 and 12 months after the treatment. The data of BCVA and central retinal thickness(CRT), before and after treatment were compared. The BCVA, CRT, subretinal fluid(SRF), intraretinal fluid(IRF), subretinal hyperreflective material(SHRM), retinal pigment epithelial detachment(PED), ellipsoidal zone(EZ)were analyzed. Patients were divided into two groups based on the Log MAR difference between the final follow-up BCVA and baseline BCVA:the vision improvement group and the vision loss group. the changes in vision before and after treatment, and the factors associated with poor vision prognosis were screened.Results:BCVA increased and CRT decreased of 1, 2, 3, 6, 12 months after treatment. The characteristics of SRF and SHRM at baseline affected the changes in BCVA after 3 months and 1 year after treatment, and the difference was statistically significant( P <0.05). PED characteristics were correlated with the recovery of CRT, and the fracture of EZ indicated the possibility of poor vision prognosis, but IRF not. No treatment-related ocular complications and systemic adverse reactions occurred during the follow-up period. Conclusions:Intravitreal injection of Conbercept for wAMD can effectively improve patients' vision, reduce macular fovea thickness, and it can improve and restore macular structure. The long-term effect is good without increasing treatment risks. SRF, SHRM, PED and EZ can be used as important indicators for comprehensive evaluation of the efficacy of anti-VEGF treatment.